After scanning the latest 2018 Terumo financials 2 things became...

After scanning the latest 2018 Terumo financials 2 things became of interest to myself:
^The Terumo General Hospital Division[the division POH deals with] revenue has been flat lining for more than 4 years.
^Terumo is making serious attempts to get a foothold into the Chinese pharmaceutical market.
According to research conducted by Chinese Research and Intelligence the following quote relates to propofol use in China:
"Main varieties of anaesthetic are lidocaine, sevoflurane and propofol, among which both sevoflurane and propofol reached its sales peak of USD 1.16 billion and USD 500 million in 2004 in global market. Propofol market in China has kept expanding despite its shrinking global counterpart. As operation number keeps rising in China, anaesthetic sales grows too, leading to a huge potential market.
As an important link of surgery, anesthesia is critical to surgery success and patient’s life. Three broad categories of anesthesia exist: general anesthesia, spinal anesthesia and regional anesthesia, among which general anesthesia dominates the market due to its high price. As the best seller in anaesthetic agents, propofol has been widely used in Chinese hospitals.
As a short-acting, intravenously administered amnestic agent with rapid onset and recovery, propofol has been included in the National List of Essential Medicines. According to CRI’s market survey, the sales value of propofol in China rose from less than CNY 200 million in 2005 to over CNY 800 million in 2014 and CAGR during this period reached 18.5%. And propofol products available in the Chinese market mainly come from AstraZeneca (Italy), Fresenius Kabi, Libang Pharmaceutical Group, Sichuan Shule Pharmaceutical Co., Ltd and B. Braun (Germany), among which AstraZeneca (Italy) had the largest market share of nearly 60% for sales value in 2014."
This detail above suggest that the Terumo interest in TPM propofol might be greater than I had previously anticipated.
Kens